The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis
Open accessAbstract
OBJECTIVE: To compare the impact of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on cardiovascular outcomes in adults taking maximally tolerated statin therapy or who are statin intolerant. DESIGN: Network meta-analysis. DATA SOURCES: Medline, EMBASE, and Cochrane Library up to 31 December 2020. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials of ezetimibe and PCSK9 inhibitors with ≥500 patients and follow-up of ≥6 months. MAIN OUTCOME MEASURES: We performed frequentist fixed-effects network meta-analysis and GRADE (grading of recommendations, assessment, development, and evaluation) to assess certainty of evidence. Results included relative risks (RR) and absolute risks per 1000 patients treated for five years for non-fatal myocardial infarction (MI), non-fatal stroke, all-cause mortality, and cardiovascular mortality. We estimated absolute risk differences assuming constant RR (estimated from network meta-analysis) across different baseline therapies and cardiovascular risk thresholds; the PREDICT risk calculator estimated cardiovascular risk in primary and secondary prevention. Patients were categorised at low to very high cardiovascular risk. A guideline panel and systematic review authors established the minimal important differences (MID) of 12 per 1000 for MI and 10 per 1000 for stroke. RESULTS: We identified 14 trials assessing ezetimibe and PCSK9 inhibitors among 83 660 adults using statins. Adding ezetimibe to statins reduced MI (RR 0.87 (95% confidence interval 0.80 to 0.94)) and stroke (RR 0.82 (0.71 to 0.96)) but not all-cause mortality (RR 0.99 (0.92 to 1.06)) or cardiovascular mortality (RR 0.97 (0.87 to 1.09)). Similarly, adding PCSK9 inhibitor to statins reduced MI (0.81 (0.76 to 0.87)) and stroke (0.74 (0.64 to 0.85)) but not all-cause (0.95 (0.87 to 1.03)) or cardiovascular mortality (0.95 (0.87 to 1.03)). Among adults with very high cardiovascular risk, adding PCSK9 inhibitor was likely to reduce MI (16 per 1000) and stroke (21 per 1000) (moderate to high certainty); whereas adding ezetimibe was likely to reduce stroke (14 per 1000), but the reduction of MI (11 per 1000) (moderate certainty) did not reach MID. Adding ezetimibe to PCSK9 inhibitor and statin may reduce stroke (11 per 1000), but the reduction of MI (9 per 1000) (low certainty) did not reach MID. Adding PCSK9 inhibitors to statins and ezetimibe may reduce MI (14 per 1000) and stroke (17 per 1000) (low certainty). Among adults with high cardiovascular risk, adding PCSK9 inhibitor probably reduced MI (12 per 1000) and stroke (16 per 1000) (moderate certainty); adding ezetimibe probably reduced stroke (11 per 1000), but the reduction in MI did not achieve MID (8 per 1000) (moderate certainty). Adding ezetimibe to PCSK9 inhibitor and statins did not reduce outcomes beyond MID, while adding PCSK9 inhibitor to ezetimibe and statins may reduce stroke (13 per 1000). These effects were consistent in statin-intolerant patients. Among moderate and low cardiovascular risk groups, adding PCSK9 inhibitor or ezetimibe to statins yielded little or no benefit for MI and stroke. CONCLUSIONS: Ezetimibe or PCSK9 inhibitors may reduce non-fatal MI and stroke in adults at very high or high cardiovascular risk who are receiving maximally tolerated statin therapy or are statin-intolerant, but not in those with moderate and low cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A meta-analysis suggests that there is a cardiovascular benefit of adding ezetimibe or PCSK9 inhibitors to treatment for people at high risk (111).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [111]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Research works printed but not linked: 1
- Pfizer. Pfizer discontinues global development of bococizumab. its investigational PCSK9 inhibitor. 2016. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor.
Cited by
Sorted by citations
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 573
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 339
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 107
Cui, D., Yu, X., Guan, Q., Shen, Y., Liao, J., Liu, Y., & Su, Z. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00321-3 · Cited by 126
Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque
Marfella, R., Prattichizzo, F., Sardu, C., Paolisso, P., D’Onofrio, N., Scisciola, L., Grotta, R. L., Frigé, C., Ferraraccio, F., Panarese, I., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.06.971 · Cited by 103
Panvascular medicine: an emerging discipline focusing on atherosclerotic diseases
Zhou, X., Yu, L., Zhao, Y., & Ge, J. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac448 · Cited by 84
Hao, Q., Aertgeerts, B., Guyatt, G. H., Bekkering, G. E., Vandvik, P. O., Khan, S. U., Rodondi, N., Jackson, R., Reny, J., Al‐Ansary, L. A., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069066 · Cited by 80
Self-citationGlobal Trends in the Epidemiology and Management of Dyslipidemia
Liu, T., Zhao, D., & Qi, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216377 · Cited by 81
Global Burden Attributable to High Low-Density Lipoprotein-Cholesterol From 1990 to 2019
Du, H., Shi, Q., Song, P., Pan, X., Yang, X., Chen, L., He, Y., Zong, G., Zhu, Y., Su, B., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.903126 · Cited by 63
Self-citationMach, F., Visseren, F. L. J., Cater, N. B., Salhi, N., Soronen, J., Ray, K. K., Delgado, V., Jukema, J. W., Laufs, U., Zamorano, J.-L., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.07.001 · Cited by 57
Gunta, S. P., O’Keefe, J. H., O’Keefe, E. L., & Lavie, C. J. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.02.007 · Cited by 44
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
Bell, A. S., Wagner, J., Rosoff, D. B., & Lohoff, F. W. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105155 · Cited by 36
Sex Differences in Cardiovascular Outcomes and Cholesterol-Lowering Efficacy of PCSK9 Inhibitors
Rivera, F. B., Cha, S. W., Aparece, J. P., Rocimo, A. M. R., Ong, B., Golbin, J. M., Alfonso, P. G., Enkhmaa, B., Khan, S. U., Cainzos‐Achirica, M., et al. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100669 · Cited by 36
Self-citationLiu, Y., Zhu, K., Peng, W., Liu, Z., & Mao, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02631-6 · Cited by 36
Luo, M., Liu, Y., Xu, X., Liu, K., Shen, C., Hu, H., He, Z., & Wu, F. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1158274 · Cited by 29
Han, D., Tzolos, E., Park, R. H., Gransar, H., Hyun, M. C., Friedman, J. D., Hayes, S. W., Thomson, L., Kwan, A. C., Budoff, M. J., et al. (2025) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2025.01.005 · Cited by 26
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab
Zimerman, A., O’Donoghue, M. L., Ran, X., Im, K., Ott, B. R., Mach, F., Zavitz, K. H., Kurtz, C. E., Monsalvo, M. L., Wang, B., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2400112 · Cited by 25
Wang, H., Mao, Y.-C., Xu, X., Zhao, S., Han, D.-D., Ge, S., Song, K., Geng, C., & Tian, Q. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1016802 · Cited by 19
Medical treatments for abdominal aortic aneurysm: an overview of clinical trials
Chen, J., Hu, L., & Liu, Z. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377747 · Cited by 18
Dimitriadis, K. S., Pyrpyris, N., Iliakis, P., Beneki, E., Adamopoulou, E., Papanikolaou, A., Konstantinidis, D., Fragkoulis, C., Κόλλιας, Α., Aznaouridis, K. A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175040 · Cited by 16
Worldwide burden attributable to diet high in red meat from 1990 to 2019
Liu, D., Shi, Q., Cheng, G., Huang, Q., & Li, S. (2022) · Archives of Medical Science · doi:10.5114/aoms/156017 · Cited by 17
Self-citationXiang, Y., Gan, L., Du, H., Hao, Q., Aertgeerts, B., Li, S., & Hu, M. (2023) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462323000296 · Cited by 15
Self-citationAssociation of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
LaFratte, C., Peasah, S. K., Huang, Y., Hall, D. L., Patel, U. B., & Good, C. B. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029707 · Cited by 15
An update on renal tubular injury as related to glycolipid metabolism in diabetic kidney disease
Feng, A., Yin, R., Xu, R., Zhang, B., & Yang, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1559026 · Cited by 18
An Update on Dyslipidemia Management and Medications: A Review
Taher, Z. A., Taher, A. A., & Radi, S. (2024) · Cureus · doi:10.7759/cureus.56255 · Cited by 16
Huang, Q., Zhou, Z., Xu, L., Zhan, P., & Huang, G. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116563 · Cited by 12
Atherogenic circulating lipoproteins in ischemic stroke
Benı́tez, S., Puig, N., Camps‐Renom, P., & Sánchez‐Quesada, J. L. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1470364 · Cited by 11
Giglio, R. V., Muzurović, E. M., Patti, A. M., Toth, P. P., Agarwal, M. A., Almahmeed, W. A., Klisic, A. N., Ciaccio, M., & Rizzo, M. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231186855 · Cited by 11
The Link between miRNAs and PCKS9 in Atherosclerosis
Mačvanin, M., Gluvic, Z. M., Klisic, A. N., Manojlovic, M. S., Suri, J. S., Rizzo, M., & Isenović, E. R. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673262124231102042914 · Cited by 13
Ding, Z., Meng, G.-X., Xue, J.-S., Liu, H., Yang, L.-S., Li, R., Mao, X., Yan, Y., Wang, D., Dong, Z., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103940 · Cited by 10
Ou, S., Liang, Q., Leng, Y., Luo, T., Xu, X., Xie, H., Gao, H., Li, J., & Xie, C. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1598897 · Cited by 9
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis
Huang, C., Wang, S., Fan, F. S., Lu, H., & Wei, J. C. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae056 · Cited by 10
de Gaetano, M. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101699 · Cited by 9
Shao, C.-L., Meng, W., Wang, Y., Liu, J., Ning, K., Hou, X., & Guo, H.-D. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113368 · Cited by 8
Iannuzzo, G., Kamboj, G., Barman, P., Dongare, S., & Jawla, S. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.10.001 · Cited by 10
Bredehorst, M., González‐González, A. I., Schürmann, L., Firmansyah, D., Muth, C., Haasenritter, J., van der Wardt, V., & Puzhko, S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1494234 · Cited by 9
Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins
Capuozzo, M., Ottaiano, A., Cinque, C., Farace, S., & Ferrara, F. (2025) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2024.12.002 · Cited by 8
Schreckenberg, R., Wolf, A., Szabados, T., Gömöri, K., Szabó, I. A., Ágoston, G., Brenner, G. B., Bencsik, P., Ferdinandy, P., Schulz, R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126512 · Cited by 8
Inclisiran in primary prevention: reality or fiction?
Gencer, B., & Mach, F. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac653 · Cited by 8
Ji, J., Wei, X., Chen, W., Wan, D., Han, W., & Liu, H. (2023) · PubMed Central · Cited by 7
Wu, X.-D., Ye, X.-Y., Liu, X.-Y., Lin, Y., Lin, X. Y., Li, Y., Ye, B.-H., & Sun, J.-C. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2389470 · Cited by 8
Du, Z., Wang, S., Yang, O., He, J., Yang, Y., Zheng, J., Zhao, H., & Cai, Y. (2024) · Health Information Science and Systems · doi:10.1007/s13755-024-00310-w · Cited by 6
Qiao, W., Feng, Y., Wen, Z., Dou, L., & Li, Y. (2026) · Drugs · doi:10.1007/s40265-025-02274-x · Cited by 8
Cleto, A. S., Schirlo, J. M., Gomes, V. H. O., Beraldo, M. L. J., Neiverth, G. S., Beltrame, M. L., Machozeki, J., & Martins, C. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16091 · Cited by 7
Trends in Lipid‐Lowering Agent Consumption in Croatia: A 25‐Year Observational Study
Belančić, A., Štiglić, M. K., Prgomet, L., Pećin, I., Reiner, Ž., & Vitezić, D. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70122 · Cited by 6
Alirocumab versus Evolocumab on Cardiovascular Outcomes: A Systematic Review and Meta-analysis
Cleto, A. S., Schirlo, J. M., Machozeki, J., & Martins, C. M. (2025) · Current Cardiology Reviews · doi:10.2174/011573403x357542250526072430 · Cited by 5
Cui, J., Wang, W., Xu, Q., Zhu, M., Li, Y., Liu, Y., & Liu, Y. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040775 · Cited by 5
Kuang, J. C., Hao, L., Zhang, M., & Yang, Z. (2025) · MedComm · doi:10.1002/mco2.70451 · Cited by 7
Schmidt, L. E., Speidl, W. S., Tsimikas, S., & Mayr, M. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad294 · Cited by 5
Hirschel, T., Vandvik, P. O., & Agoritsas, T. (2025) · BMJ Open · doi:10.1136/bmjopen-2023-083032 · Cited by 6
Self-citationPamporis, K., Karakasis, P., & Tsiachris, D. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000988 · Cited by 5
▼Inclisiran: more hope less hype
(2022) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2022.000009 · Cited by 5
Are We Using Ezetimibe As Much As We Should?
Manolis, A. S., Manolis, T. A., Mikhailidis, D. P., & Manolis, A. S. (2024) · Biomarker Insights · doi:10.1177/11772719241257410 · Cited by 5
Liuzzo, G., & Patrono, C. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac360 · Cited by 5
Løvsletten, P. O., Hunskaar, B. S., Heen, A. F., Bekkering, G. E., Poel, L. V., Zeraatkar, D., Vermandere, M., Aertgeerts, B., Delvaux, N., Achille, F., et al. (2024) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2024.111399 · Cited by 5
Self-citationLai, P., Xu, S., Liu, Z., Ling, J., Tian, K., Yan, J., Chen, D., Zhong, Y., & Xue, J. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1474472 · Cited by 5
Role of metabolic conditions in cardiorenal diseases: initiating pathways and therapeutic targeting
Wu, Y., Xu, H., Tu, X., & Gao, Z. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1701084 · Cited by 4
Duddu, S., Katakia, Y. T., Suresh, N., Chakrabarti, R., Majumder, S., & Shukla, P. C. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.168135 · Cited by 4
Quantitative Proteomics Reveal the Role of Matrine in Regulating Lipid Metabolism
Feng, H., Liu, G., Li, L., Ren, X., Jiang, Y., Hou, W., Liu, R., Liu, K., Liu, H. S., & Huang, H. (2024) · ACS Omega · doi:10.1021/acsomega.3c09983 · Cited by 4
Recent Progress of Sterol Regulatory Element-binding Proteins Role in Atherosclerosis
Zou, A., Sun, Y., Dong, W., Lu, J., & Yang, Z. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01317-8 · Cited by 5
Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
van Kleef, L. A., Michel, M. S., Alkhouri, N., Brouwer, W. P., & Schattenberg, J. M. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s559331 · Cited by 4
Kwok, M. K., & Schooling, C. M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030943 · Cited by 4
Controlling Prescribing through “Preferred Drug” Targets—The Bavarian Experience
Gollnick, J., Zeschick, N., Muth, J., Hörbrand, F., Behnke, K., Killian, P., Sebastião, M., Kühlein, T., & Donner‐Banzhoff, N. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21091174 · Cited by 3
Therapeutic Management of LDL-C: Efficacy and Economic Impact Assessment
Elshafeey, A. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12050196 · Cited by 3
Insights into Causal Cardiovascular Risk Factors from Mendelian Randomization
Schooling, C. M., & Zhao, J. (2023) · Current Cardiology Reports · doi:10.1007/s11886-022-01829-8 · Cited by 3
PCSK9 siRNA INHIBITOR INCLISIRAN AS A TREATMENT OPTION IN HYPERCHOLESTEROLEMIA: A BRIEF REVIEW
Kılıç, M. E. (2023) · TURKISH MEDICAL STUDENT JOURNAL · doi:10.4274/tmsj.galenos.2023.2023-5-1 · Cited by 3
Lipid-Lowering Therapy in PURE Poland Cohort Study
Lubieniecki, P., Wołyniec, M., Połtyn–Zaradna, K., Zatońska, K., & Szuba, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010060 · Cited by 4
Li, W., Sun, L., & Yan, S. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1375040 · Cited by 4
Ou, Z., Wang, F., Chen, Y., Liu, X., Ran, B., Yin, Y., & Cui, K. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07622-9 · Cited by 3
Improving Cardiovascular Outcomes: The Era of Personalized Therapy in Atherosclerosis
Kabłak-Ziembicka, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113077 · Cited by 3
Post-Ischemic Stroke Cardiovascular Risk Prevention and Management
Guo, Y., Pan, D., Wan, H., & Yang, J. (2024) · Healthcare · doi:10.3390/healthcare12141415 · Cited by 2
Bempedoic Acid: A Review in Cardiovascular Risk Reduction in Statin-Intolerant Patients
McGuigan, A., & Blair, H. A. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00714-9 · Cited by 4
Tu, K.-C., Chang, W., Lin, H.-W., Lin, P., Wu, Y., Lin, C., Yeh, H., Charng, M., Huang, P., Lin, T., et al. (2025) · European journal of medical research · doi:10.1186/s40001-025-02431-8 · Cited by 2
Yin, X., Shi, L., Zhang, N., Li, H., Long, J., & Yu, X. (2025) · Journal of Dermatological Treatment · doi:10.1080/09546634.2025.2482867 · Cited by 2
PCSK9 Inhibitor and Potential Decreased Risk of Neoplasms, Especially in Females: A Meta-Analysis
Wei, T., Li, Z., Lin, C., Yang, Y., Tie, C., Cai, X., Lv, F., Yang, W., & Ji, L. (2025) · Pharmaceuticals · doi:10.3390/ph18081095 · Cited by 2
PCSK9 inhibitors: a promising lipid-lowering strategy for kidney transplant recipients
Luo, B., Guo, L., & Di, W. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2604881 · Cited by 2
Genetic associations of circulating plasma proteins with cardiometabolic diseases
Zhou, R., Qiao, J., Zhang, X., Yang, X., Hong, W., Cai, L., Zhang, P., Pauklin, S., Yang, Y., Xu, Z., et al. (2026) · Genome biology · doi:10.1186/s13059-026-03962-x · Cited by 2
Fan, T., Yan, Y., Lü, Q., Li, J., & Chen, H. (2024) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.05.015 · Cited by 2
Biparatopic anti-PCSK9 antibody enhances the LDL-uptake in HepG2 cells
Li, X., Zhang, W., Shu, Y., Huo, R., Zheng, C., Qi, Q., Fu, P., Sun, J., Wang, Y., Wang, Y., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-66290-9 · Cited by 2
Wang, X., Zhou, L. J., Wang, Q., & Wu, M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0323210 · Cited by 2
Nishino, M., Egami, Y., Sugino, A., Kobayashi, N., Abe, M., Ohsuga, M., Nohara, H., Kawanami, S., Ukita, K., Kawamura, A., et al. (2025) · Heart and Vessels · doi:10.1007/s00380-025-02571-1 · Cited by 2
Moon, S. H., Ki, H. W., Yoon, N. H., Chung, K. I., Jo, H., Jin, J., Jeon, S., Sonn, S., Seo, S., Suh, J., et al. (2024) · medRxiv · doi:10.1101/2024.08.27.24312680 · Cited by 2
Positioning of PCSK9 Inhibitors in hypercholesterolemia
Chaudhry, S., & Trailokya, A. (2023) · Indian Journal of Pharmacy and Pharmacology · doi:10.18231/j.ijpp.2023.030 · Cited by 1
Ray, R., Mahmood, A., Chaudhry, R., Masmoum, M. D., Talha, M., Siddiqui, F. I., & Ullah, I. (2025) · Current Cardiology Reviews · doi:10.2174/011573403x345749250122092324 · Cited by 1
Niu, Q., Wang, Q., Chen, F., & Li, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1626681 · Cited by 1
Wisløff, T. F., Mundal, L. J., Igland, J., Svendsen, K., Bogsrud, M. P., Kristiansen, I. S., & Retterstøl, K. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf592 · Cited by 1
Kang, S., Kwon, S. U., Lee, J.-Y., Seo, S. M., Nam, C., Park, G.-M., Hong, Y. J., Lee, W. Y., Jang, J. E., & Chae, I. H. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05594-2 · Cited by 1
Singier, A., Bénard‐Laribière, A., Jarné, A., Pariente, A., Veyrac, G., & Bezin, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-40791-1 · Cited by 1
Hafez, A. H., Farina, J., Awad, K., Pereyra, M., Scalia, I. G., Sheashaa, H., Abdelfattah, F. E., Razaghi, M., Ahmed, S., Ibrahim, R., et al. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16050254 · Cited by 2
Myśliwiec, A., Leksa, D., Bartusik‐Aebisher, D., & Aebisher, D. (2026) · Journal of Applied Biomedicine · doi:10.32725/jab.2026.007 · Cited by 1
Confluence of Mendelian Randomization with Clinical Trials as To Very Low Levels of LDL Cholesterol
Chacra, A. P. M., Saldanha, A. L. R., Margeotto, A. P. P., Gasparoto, A. L. V., Ampuero, M. S. S., Castro, L. F. D., & Martinez, T. L. D. R. (2024) · Clinical Medicine And Health Research Journal · doi:10.18535/cmhrj.v4i1.304 · Cited by 1
Age-related disease: Cardiovascular system
Nilsson, P. M., Fossel, M., Bean, J., & Khera, N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15500-0.00010-4 · Cited by 2
Aggressive low-density lipoprotein (LDL) lowering for primary prevention: still an elusive goal
Sepehrinia, M., Homayounfar, R., & Farjam, M. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02280-0 · Cited by 1
Ezetimibe mediated RPS6KA2 inhibits colorectal cancer proliferation via PCSK9/MAPK signaling pathway
Wang, Y., Wang, Y., Gao, H., Chen, L., Zheng, S., Chen, Y., Shi, H., & Han, A. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100899 · Cited by 1
Schirmer, B., & Schuler, J. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_11 · Cited by 1
Sell, J. K., & Nunez, J. J. (2025) · doi:10.1093/med/9780197812631.003.0029 · Cited by 1
White, H. D. (2022) · Heart · doi:10.1136/heartjnl-2022-321063 · Cited by 1
Letter: PCSK9 inhibitor for liver transplant patients during the post‐statin era?
Wang, J., Wu, J., He, Z., & Xin, H. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17258 · Cited by 1
Chou, O. H. I., Li, L., Chung, C. T., Lü, L., Lee, Q., Pui, H. H. H., Leung, B. K. H., Chang, C., Liu, T., Wai, A. K. C., et al. (2023) · medRxiv · doi:10.1101/2023.09.23.23296003 · Cited by 1
Metadata
- Authors
- Khan, S. U., Yedlapati, S. H., Lone, A. N., Hao, Q., Guyatt, G., Delvaux, N., Bekkering, G. E. (., Vandvik, P. O., Riaz, I. B., Li, S., Aertgeerts, B., & Rodondi, N.
- Affiliations
- Houston Methodist (US)
- Erie County Medical Center (US)
- Guthrie Robert Packer Hospital (US)
- Sichuan University (CN)
- McMaster University (CA)
- KU Leuven (BE)
- University of Oslo (NO)
- Mayo Clinic (US)
- University of Bern (CH)
- Corresponding author
- Khan, Safi U
- ORCID
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2022-05-04
- Volume
- 377
- Pages
- e069116
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W4229000569
- Cited by
- 151
- References
- 41
- Citations by year
- 2026: 36 · 2025: 40 · 2024: 34 · 2023: 26 · 2022: 15
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
- Locations
- BMJ (publishedVersion)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion, cc-by-nc)
- Lirias (submittedVersion, cc-by-nc)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by-nc)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- PCSK9 inhibitors, ezetimibe, statin therapy, statin intolerance, cardiovascular risk reduction, myocardial infarction, stroke, all-cause mortality, cardiovascular mortality, hypercholesterolemia, LDL cholesterol lowering, minimal important difference, cardiovascular disease prevention, combination lipid-lowering therapy, LDL cholesterol targets
- MeSH terms
- Ezetimibe, Proprotein Convertase 9, Heart Disease Risk Factors, PCSK9 Inhibitors, Adult, Anticholesteremic Agents, Cardiovascular Diseases, Humans, Myocardial Infarction, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
